Is Catabasis Pharmaceuticals, Inc. (CATB) a Buy, Sell, or Hold?
NASDAQ : CATB
Catabasis Pharmaceuticals, Inc.
$8.54 USD
-$0.64 (-6.97%)
- Volume
- 98.87K
- Average Volume
- 528.92K
- Market Capitalization
- $234.86M
- P/E Ratio
- -5.02
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $10.26
- Year Low
- $1.25
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.78
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jill Milne |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CATB |
| CUSIP | 14875P206 |
| CIK | 0001454789 |
| Web | http://www.catabasis.com |
| Phone | 16173491971 |
| Currency | USD |
| Employees | 20 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 10.78 |
| Quick Ratio | 10.78 |
| Cash Ratio | 4.09 |
Sales & Book Value
| Annual Sales | -$ |
| Price / Sales | 332.66 |
| Cash Flow | 0.00 |
| Price / Cash Flow | -2.28 |
| Price / Book | 0.00 |
Price Target and Rating
| Average Stock Price Forecast | |
| High Stock Price Forecast | |
| Low Stock Price Forecast | |
| Forecast Upside/Downside | % |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 6 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$1.68 |
| Trailing P/E Ratio | -5.02 |
| PEG Ratio | -0.05 |
| P/E Growth | -0.05 |
| Net Income | -$94.26M |
| Net Margin | -13938.24% |
| Pretax Margin | -13938.24% |
| Return on Equity | -37.70% |
| Return on Assets | -36.20% |
Financials Score
| AltmanZ Score | |
| Piotroski Score | |
| Working Capital | - |
| Total Assets | - |
| Ebit | - |
| Market Cap | - |
| Total Liabilities | - |
Poll Results
About Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Stock
Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic treatments primarily within the United States. Their leading experimental drug, edasalonexent, is an oral small molecule undergoing Phase III clinical trials for Duchenne Muscular Dystrophy (DMD), functioning by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells. Additionally, the company is developing CAT-5571 as a potential treatment for cystic fibrosis. Catabasis also engages in collaborative research, including a preclinical partnership with the Jain Foundation to investigate edasalonexent for dysferlinopathy, and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 for both drug-sensit ... ive and drug-resistant tuberculosis. The company was established in 2008 and is based in Boston, Massachusetts.
Frequently Asked Questions
-
What is the current Catabasis Pharmaceuticals, Inc. (CATB) stock price?
-
Catabasis Pharmaceuticals, Inc.(NASDAQ:CATB) stock price is $8.54 in the last trading session. During the trading session, CATB stock reached the peak price of $9.21 while $8.48 was the lowest point it dropped to. The percentage change in CATB stock occurred in the recent session was --6.97% while the dollar amount for the price change in CATB stock was -$0.64.
-
CATB's industry and sector of operation?
-
The NASDAQ listed CATB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CATB?
-
|
|
|
|
| -
How many employees does CATB have?
-
Number of CATB employees currently stands at 20. CATB operates from 100 High Street, 28th Floor, Boston, MA 02139, US.
-
Link for CATB official website?
-
Official Website of CATB is: http://www.catabasis.com
-
How do I contact CATB?
-
CATB could be contacted at phone #16173491971 and can also be accessed through its website. CATB operates from 100 High Street, 28th Floor, Boston, MA 02139, US.
-
How many shares of CATB are traded daily?
-
The average number of CATB shares traded daily for last 3 months was 528.92K.
-
What is the market cap of CATB currently?
-
The market value of CATB currently stands at $234.86M with its latest stock price at $8.54